Noble Financial Thinks Ayala Pharmaceuticals’ Stock is Going to Recover
27 July 2022 - 10:25PM
TipRanks
Noble Financial analyst Robert LeBoyer reiterated a Buy rating on
Ayala Pharmaceuticals (AYLA – Research Report) today and set a
price target of $12.00. The company's shares closed last Tuesday at
$1.69, close to its 52-week low of $0.70. According to
TipRanks.com, LeBoyer is a 4-star analyst with an average return of
8.9% and a 33.6% success rate. LeBoyer covers the Healthcare
sector, focusing on stocks such as Lineage Cell Therapeutics,
Onconova Therapeutics, and PDS Biotechnology. The word on The
Street in general, suggests a Moderate Buy analyst consensus rating
for Ayala Pharmaceuticals with a $15.00 average price target.
https://www.tipranks.com/news/blurbs/noble-financial-thinks-ayala-pharmaceuticals-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
Ayala Pharmaceuticals (NASDAQ:AYLA)
Historical Stock Chart
From May 2023 to May 2023
Ayala Pharmaceuticals (NASDAQ:AYLA)
Historical Stock Chart
From May 2022 to May 2023
